Trial Profile

Phase II, Open Label Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC) for Advanced Breast Cancer Patients, With Biomarkers Analysis to Characterize Response/Resistance to Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab-deruxtecan (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms DAISY

Most Recent Events

04 Sep 2024 According to a Daiichi Sankyo media release , a mini oral session will feature a supplementary biomarker analysis from this trial in Breast Cancer at ESMO
12 Dec 2023 New source identified and integrated: (European Clinical Trials Database: EudraCT2018-004868-57).
06 Dec 2023 Planned End Date changed from 30 Mar 2025 to 22 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com